Overall survival (OS) in the IMELDA randomized phase III trial of maintenance bevacizumab (BEV) with or without capecitabine (CAP) for HER2-negative metastatic breast cancer (mBC)

Gligorov J., Bines J., Alba E., Mustacchi G., Cinieri S., Gupta V., ...More

37th Annual CTRC-AACR San Antonio Breast Cancer Symposium, San-Antonio, Northern Mariana Islands, 9 - 13 December 2014, vol.75 identifier

  • Publication Type: Conference Paper / Summary Text
  • Volume: 75
  • Doi Number: 10.1158/1538-7445.sabcs14-p2-17-01
  • City: San-Antonio
  • Country: Northern Mariana Islands
  • Hacettepe University Affiliated: Yes